We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The company asked a federal judge to force the plaintiffs to take their antitrust cases to arbitration, citing an arbitration clause in its distribution agreement. Read More
Internet service providers, social media companies, and other prominent members of the Internet economy need to help identify and remove illegal offers to distribute opioids, FDA Commissioner Scott Gottlieb said at the National Rx Drug Abuse and Heroin Summit in Atlanta, Georgia. Read More
The National Institutes of Health launched a new initiative to address the opioid crisis, increasing funding for research on opioid misuse, addiction and pain from approximately $600 million in fiscal year 2016 to $1.1 billion for fiscal 2018. Read More
State Senator Leah Vukmir (R), who sponsored the state senate version of the bill, said allowing such substitutions at the pharmacy level could save consumers as much as 20 percent. Read More
The Prescription Interdiction and Litigation Task Force is looking at existing lawsuits against opioid manufacturers by state and local governments to offer federal assistance where possible. Read More
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee is requesting that sponsors of antiretrovirals submit, by May 8, supplementary safety information related to the risk of autoimmune hepatitis. Read More
Wisconsin and West Virginia passed laws allowing pharmacists to substitute interchangeable biosimilars, bringing the total number of states with such laws to 40. Read More
Three senators wrote to Tri-Source Pharma demanding an explanation for dramatic price spikes for the company’s off-patent cancer drug lomustine. Read More